AVR 0.00% $18.20 anteris technologies ltd

For those who are interested, page-10

  1. 34 Posts.
    lightbulb Created with Sketch. 28
    “It’s quite an exceptional company with a medical advisory board of the who’s who of the cardiovascular space,” Pachacz says.

    He says AVR has had some exceptionally good results in an early feasibility study with plans for a pivotal study involving around 200 patients.

    “There’s two main competitors – Edwards Lifesciences and Medtronic,” he says.“So this company will probably get acquired at some point by one of those two companies, I would’ve thought”
    ———————————————

    That planned pivotal study patient number of (only) 200 is new to me, much smaller than 1000+ patients I have seen mentioned elsewhere on this forum. Wonder if that would lead to an early 2025 FDA approval perhaps.
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.